[DNA content analysis and detection of c-myc and p53 products using flow cytometry in resected lung cancer cases].
We quantitatively analyzed the c-myc and p53 products using flow cytometry in 28 cases of resected lung cancer and one case each of chorio-carcinoma, plasmacytoma, malignant mesothelioma and sclerosing hemangioma. In the lung cancer cases, c-myc and p53 products were detected in 10 cases (35%) and 7 cases (21%), respectively. These rates are higher than the DNA abnormal expression rates of the c-myc and p53 genes (15% and 12%, respectively) in our own data. In the adenocarcinoma of lung cancer cases, c-myc and p53 products were detected in 9 cases (53%) and 5 cases (29%), respectively. Among the squamous cell carcinoma cases, there were one case (11%) of c-myc expression and one case (11%) of p53 expression. DNA content analysis of the lung cancer patients revealed 7 cases of DNA diploidy and 21 cases of DNA aneuploidy. All 10 c-myc-positive cases showed DNA aneuploidy; thus the positive rate for c-myc products in the DNA aneuploidy cases was significantly different compared with the DNA diploidy cases (p < 0.05). In the sclerosing hemangioma case, we detected both c-myc and p53 products. Sclerosing hemangioma has been thought to be a benign tumor, but it may be a malignant tumor.
Chiba
W
W
Respiratory Disease Center, Kyoto-Katsura Hospital.
Sawai
S
S
Ikeda
S
S
Morimoto
K
K
Wazawa
H
H
Hanawa
T
T
Yamashita
N
N
Matsui
T
T
Hatakenaka
R
R
Matsubara
Y
Y
D000230:Adenocarcinoma / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000235:genetics; D004273:DNA, Neoplasm / Q000032:analysis*; D005434:Flow Cytometry; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D011003:Ploidies; D016271:Proto-Oncogene Proteins c-myc / Q000032:analysis*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
D004273:DNA, Neoplasm; D016271:Proto-Oncogene Proteins c-myc; D016159:Tumor Suppressor Protein p53